Displaying drugs 2701 - 2725 of 4555 in total
TAFA-93
TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation, the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment of coronary...
Investigational
OSI-930
OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small...
Investigational
TAK-901
TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others.
Investigational
Matched Iupac: … 5-[3-(ethanesulfonyl)phenyl]-3,8-dimethyl-N-(1-methylpiperidin-4-yl)-9H-pyrido[2,3-b]indole-7-carboxamide …
SR-9009
SR-9009 is a REV-ERB agonist. SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues .
Experimental
SR-9011
SR-9011 is a REV-ERB agonist. SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues .
Experimental
GS-9191
GS-9191 is under investigation in clinical trial NCT00499967 (Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts).
Investigational
Matched Iupac: … 2-methylpropyl (2S)-2-{[({2-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]ethoxy}methyl)({[(2S)-1-(2-methylpropoxy …
ILS-920
ILS-920 is under investigation in clinical trial NCT00827190 (Study Evaluating Single Ascending Doses Of ILS-920).
Investigational
REC-994
REC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous malformation (CCM).
Investigational
OBI-999
Investigational
WRR-99
Experimental
AGF-94
Investigational
BI-187004
Investigational
8-azaguanine
8-azaguanine is one of the early purine analogs showing antineoplastic activity. It functions as an antimetabolite and is easily incorporated into ribonucleic acids.
Experimental
Matched Iupac: … 5-amino-3H,6H,7H-[1,2,3]triazolo[4,5-d]pyrimidin-7-one …
CT-001
Investigational
8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-
Experimental
Matched Name: … 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H- …
Matched Iupac: … 8-[(2H-1,3-benzodioxol-5-yl)methyl]-9-butyl-9H-purin-6-amine …
Matched Iupac: … 8-[(2H-1,3-benzodioxol-5-yl)methyl]-9-butyl-9H-purin-6-amine …
Histidine
An essential amino acid that is required for the production of histamine.
Investigational
Nutraceutical
Matched Salts cas: … 13870-80-9 …
Matched Mixtures name: … Aminosyn II 7% With 50% Dextrose ... Aminosyn II 7% With 10% Dextrose ... Aminosyn II 7% M In 10% Dextrose(dual Chamber) …
Matched Mixtures name: … Aminosyn II 7% With 50% Dextrose ... Aminosyn II 7% With 10% Dextrose ... Aminosyn II 7% M In 10% Dextrose(dual Chamber) …
Alanine
Alanine is a non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system.
Nutraceutical
Matched Mixtures name: … Aminosyn II 7% With 50% Dextrose ... Aminosyn II 7% With 10% Dextrose ... Aminosyn II 7% M In 10% Dextrose(dual Chamber) …
5-deoxyflavanone
5-deoxyflavanone is a solid. This compound belongs to the flavanones. These are compounds containing a flavan-3-one moiety, whose structure is characterized by a 2-phenyl-3,4-dihydro-2H-1-benzopyran bearing a ketone at the carbon C3.
Experimental
Matched Iupac: … (2S)-7-hydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-4-one …
SB-269970
SB-269970 is an experimental drug developed by GlaxoSmithKline. In the studies performed with this agent, it has been suggested that SB-269970 acts either as a selective antagonist or inverse agonist of the serotonin receptor 7 (5-HT7).[A31816,A31817]
Investigational
Matched Description: … suggested that SB-269970 acts either as a selective antagonist or inverse agonist of the serotonin receptor 7 …
HPA-23
HPA-23 is an investigational antiviral compound.
Investigational
Matched Synonyms: … Ammonium 21-tungsto-9-antimoniate …
Displaying drugs 2701 - 2725 of 4555 in total